Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Vaxil Bio (VXL) Stock Price & Analysis

22 Followers

VXL Stock Chart & Stats

CA$0.11CA$0.00(0.00%)
At close: 4:00 PM EST
C$0.1C$0.125C$0.15C$0.175Aug 26Sep 8Sep 17Oct 6Oct 19Nov 4
Day’s Range
CAD 0.11 - CAD 0.11
52-Week Range
CAD 0.10 - CAD 0.29
Previous Close
CAD 0.11
Volume
N/A
Average Volume (3M)
1,528
Market Cap
CAD 438.24K
Enterprise Value
CAD 253.12K
Total Cash (Recent Filing)
CAD 464.00K
Total Debt (Recent Filing)
CAD 0
Price to Earnings (P/E)
1.1
Beta
-0.83
Next Earnings
Nov 25, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

A debt-free balance sheet reduces interest expense, refinancing exposure, and solvency pressure while the company funds clinical research. This provides greater financial flexibility than a similarly early-stage biotechnology company carrying material borrowing obligations.

Positive Equity

Persistently positive equity indicates that liabilities have not exceeded the company’s recorded asset base. Although equity has fluctuated, this balance-sheet cushion can support continued operations and offers more resilience than a business already operating with negative book capital.

Improving Cash-Burn Trend

The reduction in negative operating and free cash flow suggests some improvement in cash consumption compared with earlier periods. The company is not self-funding yet, but a sustained reduction in burn could extend funding capacity and moderate future financing pressure.

Bears Say

No Reported Revenue

The absence of reported revenue means Vaxil Bio has not demonstrated recurring commercial demand or an established product monetization engine. This leaves future funding dependent on development progress and potential transactions rather than internally generated sales.

Persistent Operating Losses

Persistent negative EBIT shows that the core business remains structurally unprofitable and has not yet converted research activity into operating earnings. Without a demonstrated path to positive operating margins, continued development will require substantial financial support.

Ongoing Cash Burn

Negative operating and free cash flow in every reported period indicates that the company cannot currently fund its activities from operations. The mismatch between positive recent net income and negative cash flow also suggests earnings are not translating into durable liquidity.

Vaxil Bio News

VXL FAQ

What was Vaxil Bio’s price range in the past 12 months?
Vaxil Bio lowest stock price was C$0.10 and its highest was C$0.29 in the past 12 months.
What is Vaxil Bio’s market cap?
Vaxil Bio’s market cap is C$438.24K.
When is Vaxil Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Vaxil Bio’s earnings last quarter?
Vaxil Bio released its earnings results on Aug 24, 2026. The company reported -C$0.016 earnings per share for the quarter.
Is Vaxil Bio overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Vaxil Bio pay dividends?
Vaxil Bio does not currently pay dividends.
What is Vaxil Bio’s EPS estimate?
Vaxil Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio have?
Vaxil Bio has 3,984,020 shares outstanding.
What happened to Vaxil Bio’s price movement after its last earnings report?
Vaxil Bio reported an EPS of -C$0.016 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vaxil Bio?
Currently, no hedge funds are holding shares in TSE:VXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology